USPTO Examiner MARTIN PAUL C - Art Unit 1653

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18757539PREPARATION OF A PHOSPHOLIPID COMPOSITION/NANO LIQUID PRODUCT USEFUL IN TREATING BURNS AND INCREASING THE EFFECT OF SCAR HEALINGJune 2024October 2024Allow410NoNo
18750994COMPOSITIONS FOR INHIBITING ANAEROBIC MICROORGANISMSJune 2024November 2024Allow500YesNo
18418822METHODS FOR TREATMENT OF MENOPAUSAL SYMPTOMSJanuary 2024April 2024Allow200YesNo
18400485METHODS OF FORMING BIOCHEMICAL SCAFFOLDS FOR ENHANCING MENTAL FUNCTION AND ACUITYDecember 2023February 2025Allow1400YesNo
18394017TUNABLE NEURONAL NETWORK AND AN ARTIFICIAL EYEDecember 2023November 2025Abandon2221NoNo
18381072CLOSED-LOOP SYSTEM FOR GROWTH OF AQUATIC BIOMASS AND GASIFICATION THEREOFOctober 2023April 2025Abandon1801NoNo
18379644METHOD FOR INFECTING CELLS WITH VIRUSOctober 2023March 2025Allow1731NoNo
18469239TREATED DRIED BLOOD SAMPLE FOR DETECTION OF HEAVY METALS IN DRIED BLOODSeptember 2023July 2025Allow2221YesNo
18464101METHODS OF USING NATURAL AND ENGINEERED ORGANISMS TO PRODUCE SMALL MOLECULES FOR INDUSTRIAL APPLICATIONSeptember 2023June 2025Abandon2111NoNo
18451071A PHOSPHOLIPID COMPOSITION AND ITS USE IN THE NANO LIQUID PRODUCT CONTAINING CURCUMIN HAVE THE ABILITY TO TREATING BURNS AND INCREASING THE EFFECT OF SCAR HEALINGAugust 2023February 2025Abandon1830NoNo
18362294DESIGNED BACTERIAL COMPOSITIONSJuly 2023November 2024Abandon1601NoNo
18358637METHOD AND SYSTEM FOR PRODUCTION OF ADENOSINE TRIPHOSPHATEJuly 2023January 2025Abandon1801NoNo
18324518IDENTIFYING STATUS OF MALE FERTILITY BY DETERMINING SPERM CAPACITATIONMay 2023May 2025Abandon2311NoNo
18198732METHODS OF CELL CULTURE FOR ADOPTIVE CELL THERAPYMay 2023September 2025Abandon2821NoNo
18316945COMPOSITIONS FOR THE TREATMENT OF NON-ARTICULAR CARTILAGE-ASSOCIATED BONE CONDITIONSMay 2023October 2024Abandon1721NoNo
18306483COMPOSITION AND METHODS FOR TREATMENT OR PROPHYLAXIS OF CORONAVIRUS AND CANCERSApril 2023March 2025Allow2220YesNo
18194632PERISTALTIC PROPULSION DEVICE AND SYSTEM AND METHODS OF USE THEREOFApril 2023June 2025Abandon2731NoNo
18120313METHOD FOR RETROFITTING AN EXISTING PLANT WITH A BRAN FRACTIONATION PROCESSMarch 2023September 2024Allow1811YesNo
18171694TISSUE ORGANOIDSFebruary 2023March 2026Abandon3741YesNo
18111702Method of Enhancing Mental Function and Acuity by Delivering Biochemical ScaffoldsFebruary 2023June 2023Allow410NoNo
18169061COMPOSITIONS FOR INHIBITING ANAEROBIC MICROORGANISMSFebruary 2023March 2024Allow1311YesNo
18169073TREATMENT OF INFLAMMATORY BOWEL DISEASES THROUGH ADMINISTRATION OF ENTERIC AEROBIZATION THERAPYFebruary 2023March 2024Allow1311YesNo
18169095METHODS FOR INHIBITING ANAEROBIC MICROORGANISMSFebruary 2023February 2024Allow1211YesNo
18098377EXTRACELLULAR VESICLES FROM PREVOTELLAJanuary 2023July 2024Abandon1801NoNo
18058660COMBINATION OF PHARMACOLOGICAL AND MICROFLUIDIC FEATURES FOR IMPROVED PLATELETS PRODUCTIONNovember 2022February 2025Abandon2720NoNo
17976341Methods for Managing Adverse Events in Patient Populations Requiring TransfusionOctober 2022March 2025Abandon2931YesNo
17961836Biochemical Scaffolds for Modulating Cell FunctionOctober 2022January 2023Allow410NoNo
17868079AQUEOUS SOLUTION OF BURLULIPASE COMPRISING CALCIUM IONSJuly 2022July 2025Abandon3651YesYes
17852965METHOD FOR PRODUCING MALTITOL, WITH AN INCREASED YIELDJune 2022July 2024Abandon2510NoNo
17789653Mammalian Cells Secreting GDNF and Their Therapeutic UseJune 2022January 2026Abandon4201NoNo
17789128COMBINATION OF A PROTEASOME INHIBITOR AND A HDAC INHIBITOR AND ITS USE FOR THE TREATMENT OF GENETIC DISEASES LINKED TO A PROTEIN CONFORMATIONAL DISORDERJune 2022February 2026Abandon4401NoNo
17837763PREVENTING ADHESION OF BACTERIAJune 2022March 2026Abandon4540NoYes
17804211FLUIDIC PROCESSING WORKSTATIONMay 2022November 2025Abandon4201NoNo
17748664METHOD FOR INFECTING CELLS WITH VIRUSMay 2022July 2023Allow1411NoNo
17737578COAGULOGEN-FREE CLARIFIED LIMULUS AMEBOCYTE LYSATEMay 2022March 2025Allow3440YesYes
17732639Biochemical Scaffolds for Modulating Cell FunctionApril 2022July 2022Allow300YesNo
17729608METHOD FOR PRODUCING A CULTURED CELL SHEET FOR TISSUE REGENERATIONApril 2022June 2024Allow2620YesNo
17655485METHODS OF PREPARING PH-STABILIZED AND HEAT-STERILIZED ORGAN PRESERVATION AND/OR PERFUSION SOLUTIONSMarch 2022October 2023Allow1910YesNo
17674831FREEZE-DRIED PLATELET DERIVATIVE COMPOSITIONS FOR TREATING ANTICOAGULANT-INDUCED COAGULOPATHYFebruary 2022May 2025Abandon3921NoNo
17673773FREEZE-DRIED PLATELET DERIVATIVE COMPOSITIONS FOR TREATING ANTIPLATELET-INDUCED COAGULOPATHYFebruary 2022November 2025Abandon4501NoNo
17633936CELL CULTURING METHOD USING SMALL-PIECE POROUS MEMBRANEFebruary 2022January 2026Abandon4711NoNo
17665753FREEZE-DRIED POLYMER COMPOSITIONS FOR MIXING WITH PLATELET RICH PLASMA TO FORM IMPLANTS FOR TISSUE REPAIR AND/OR COMPOSITIONS FOR THERAPEUTIC INTRA-ARTICULAR INJECTIONSFebruary 2022August 2024Abandon3121NoNo
17650220VIRAL CONJUNCTIVITIS TREATMENT USING RANPIRNASE AND/OR AMPHINASEFebruary 2022March 2026Abandon4941NoNo
17650055TREATMENT OF INFLAMMATORY BOWEL DISEASES THROUGH ADMINISTRATION OF ENTERIC AEROBIZATION THERAPYFebruary 2022February 2024Allow2420NoNo
17556985IMMUNOTHERAPY FOR OPIOID ADDICTIONDecember 2021October 2024Abandon3421NoNo
17619755DECELLULARIZATION METHODDecember 2021July 2025Abandon4301NoNo
17542021GLUCOSE-RESPONSIVE INSULIN DELIVERY MICRONEEDLE SYSTEMDecember 2021March 2024Abandon2711NoNo
17533269METHOD OF TREATING CORNEAL PATHOLOGIES WITH OPHTHALMIC COMPOSITION OF UMBILICAL CORD BLOOD PLASMANovember 2021January 2024Abandon2611NoNo
17530693SPALAX FIBROBLAST-DERIVED ANTI-CANCER AGENTSNovember 2021August 2025Abandon4501NoNo
17521607ALKYLAMINE FUNCTIONALISED SUBSTRATE FOR DELIVERING CELLS TO A SITE AND METHODS OF USE OF THE FUNCTIONALISED SUBSTRATENovember 2021January 2026Abandon5161YesNo
17521401WET GRANULATED CELL CULTURE MEDIUM AND PREPARATION METHOD THEREFORNovember 2021December 2024Allow3700YesNo
17519252Composition For Inhibiting Proliferation of Influenza VirusNovember 2021December 2022Abandon1320YesNo
17607773USE OF CAP-SCORE IN IDENTIFICATION OF A REPRODUCTIVE APPROACH IN MEN SUFFERING FROM VARICOCELEOctober 2021May 2025Abandon4201NoNo
17607146Cultivation and Treatment of Plants for the Production of Plant-Derived DrugsOctober 2021November 2025Allow4951YesNo
17480273OPTIMIZED METHOD FOR PRODUCING A COMPOSITION CONTAINING ISOMALTULOSESeptember 2021November 2023Abandon2610NoNo
17440266METHODS OF PROMOTING CELLULAR MATURATION WITH AMPK ACTIVATORSSeptember 2021August 2025Abandon4611NoNo
17477019CLOSED SYSTEM DEVICE AND METHODS FOR GAS PERMEABLE CELL CULTURE PROCESSSeptember 2021August 2023Allow2310YesNo
17412523COMPOSITION AND METHOD FOR TREATING OR PROPHYLAXIS OF CORONAVIRUS AND CANCERSAugust 2021February 2025Allow4231YesYes
17431818SOLUTIONS AND METHODS FOR ORGAN PRESERVATIONAugust 2021July 2025Abandon4721NoNo
17398328Method for Generating Human Multipotent Mammary Stem Cells From Normal Primary Breast Luminal CellsAugust 2021August 2023Allow2410NoNo
17264148METHOD FOR FABRICATING MULTI-LAYERED CELL SHEET AND MULTI-LAYERED SHEET FABRICATED BY USING THE SAMEAugust 2021February 2025Abandon4801NoNo
17425687TREATING THE CAUSATIVE AGENT IN ADHESIOGENESISJuly 2021February 2026Abandon5521NoNo
17362524INHIBITION AND TREATMENT OF GASTROINTESTINAL BIOFILMSJune 2021September 2023Abandon2610NoNo
17418713COMPOSITION FOR CONVERTING INSULIN PRECURSOR INTO INSULIN ENZYME AND METHOD FOR CONVERTING INSULIN PRECURSOR INTO INSULIN BY USING SAMEJune 2021January 2025Abandon4331NoNo
17304447ENTERIC AEROBIZATION THERAPYJune 2021November 2023Allow2960YesNo
17343349SEPARATION OF WAX AND FIBERS FROM PLANTSJune 2021September 2023Abandon2710NoNo
17340172COMPOSITIONS FOR PROTECTING SKIN COMPRISING DNA REPAIR ENZYMES AND PHYCOBILIPROTEINJune 2021December 2025Abandon5431YesNo
17326442METHOD AND AN APPARATUS FOR AN ENZYMATIC HYDROLYSIS, A LIQUID FRACTION AND A SOLID FRACTIONMay 2021February 2025Allow4431YesNo
17291065METHOD FOR ASSESSING THE ABILITY OF A SUBSTANCE OR OF A COMPOSITION TO PREVENT, SLOW OR ELIMINATE THE SIGNS OF AGEING OF THE SKIN OR OF THE LIPSMay 2021September 2025Abandon5231NoNo
17241310IMMUNOTOLERANCE WITH HEAT SHOCK PROTEINSApril 2021September 2024Abandon4101NoNo
17235646METHODS AND COMPOSITIONS FOR THE TREATMENT OF SYMPTOMS OF NEUROLOGICAL AND MENTAL HEALTH DISORDERSApril 2021November 2025Abandon5541NoNo
17234728COMPOSITIONS AND METHODS FOR ENHANCED DELIVERY OF ANTIVIRAL AGENTSApril 2021August 2024Abandon4021NoNo
17285705ANTI-PATHOGENIC ACTIVITY OF A BIFUNCTIONAL PEPTIDOGLYCAN/CHITIN HYDROLASEApril 2021June 2025Allow5050YesNo
17279820METHODS AND COMPOSITIONS FOR BIOPROTECTION OF TOMATOES FROM CLAVIBACTER MICHIGANENSIS SUBSP. MICHIGANENSISMarch 2021August 2025Abandon5341YesNo
17197125METHODS FOR COLLECTING AND TESTING BACTERIA CONTAINING SAMPLES FROM WITHIN THE GASTROINTESTINAL TRACTMarch 2021October 2022Allow1931YesNo
17186344COMPOSITIONS AND METHODS FOR ASSESSING TOXICITY USING DYNAMIC BH3 PROFILINGFebruary 2021December 2023Abandon3311NoNo
17182964Detection of Reversal of an Anticoagulant Using a Clotting AssayFebruary 2021December 2025Abandon5851YesNo
17165718DETECTION AND ISOLATION OF MYELOID-DERIVED SUPPRESSOR CELL SUBPOPULATIONSFebruary 2021July 2024Abandon4201NoNo
17262556METHODS FOR PRECISION THERAPEUTIC TARGETING OF HUMAN CANCER CELL MOTILITY AND KITS THEREOFJanuary 2021February 2026Abandon6022NoNo
16973929Recombinant Protease Inhibitor-Containing Compositions, Methods for Producing Same and Uses ThereofDecember 2020October 2025Abandon5831NoYes
17114486METHODS AND KITS FOR TOPICAL APPLICATION, REMOVAL, AND INACTIVATION OF THERAPEUTIC OR COSMETIC TOXIN COMPOSITIONSDecember 2020January 2026Abandon6040NoYes
17077770BIFIDOBACTERIA FOR REDUCING FOOD, ENERGY AND/OR FAT INTAKEOctober 2020June 2023Abandon3210NoNo
17071303Mammalian Lung Spheroids and Lung Spheroid Cells and Uses ThereofOctober 2020January 2024Allow3921YesNo
17038391ADMINISTRATION OF ASTAXANTHIN FOR MUSCLE ATROPHYSeptember 2020October 2023Abandon3720NoNo
17032811DISPOSABLE SENSOR CHIP WITH REAGENT INCLUDING 2-SUBSTITUTED BENZOTHIAZOLYL-3-SUBSTITUTED PHENYL-5-SUBSTITUTED SULFONATED PHENYL-2H-TETRAZOLIUM SALTSeptember 2020May 2023Allow3110NoNo
17032893Probiotic Delivery SystemsSeptember 2020September 2024Abandon4731NoNo
16981181COMPOSITIONS AND METHODS FOR TREATING THYROID EYE DISEASESeptember 2020December 2025Abandon6051YesNo
17000285AUTOMATED YEAST BUDDING MEASUREMENTAugust 2020June 2023Abandon3410NoNo
16943487PROCESS FOR THE PRODUCTION AND PURIFICATION OF THE COLLAGENASE ENZYME FROM VIBRIO ALGINOLYTICUSJuly 2020November 2022Allow2700YesNo
16942415MICROWELL PLATE WITH LAMINATED MICRO EMBOSSED FILM BOTTOMJuly 2020May 2023Abandon3310NoNo
16936025ENHANCED VIRAL DELIVERY FORMULATIONJuly 2020July 2025Abandon6041YesNo
16961098Cell Reprogramming TherapyJuly 2020June 2024Abandon4701NoNo
16917450Methods of Using Natural and Engineered Organisms to Produce Small Molecules for Industrial ApplicationJune 2020November 2023Abandon4020NoNo
16955726ERYTHROCYTES FOR DRUG DELIVERYJune 2020June 2024Abandon4821NoNo
16898203CLOSED-LOOP SYSTEM FOR GROWTH OF AQUATIC BIOMASS AND GASIFICATION THEREOFJune 2020December 2023Abandon4211NoNo
16895903PREVENTIVE OR THERAPEUTIC AGENT FOR MUSCLE INJURYJune 2020November 2024Abandon5340YesNo
16885651MEMBRANOUS TISSUE WITH EVENLY SPACED ELEVATED PROJECTIONS ON ONE SIDE AND CONCAVE DEPRESSIONS ON THE OTHER SIDE METHOD AND USEMay 2020May 2023Abandon3621YesNo
16839204Drug Delivery System Comprising Nanocarrier Loaded with Urate Oxidase and Metal-Based Nanoparticle Capable of Degrading Hydrogen Peroxide and Pharmaceutical Composition Comprising the SameApril 2020November 2023Abandon4421YesNo
16840255HYALURONIDASE COMPOSITIONS AND METHODS OF USING SAME FOR DETERMINING THE ETIOLOGY OF PERI-ORBITAL PUFFINESSApril 2020November 2021Allow2050NoNo
16836068INTEGRATED SYSTEM FOR THE CULTIVATION OF ALGAE OR PLANTS AND THE PRODUCTION OF ELECTRIC ENERGYMarch 2020July 2023Abandon4020NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MARTIN, PAUL C.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
34
Examiner Affirmed
23
(67.6%)
Examiner Reversed
11
(32.4%)
Reversal Percentile
48.7%
Lower than average

What This Means

With a 32.4% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
111
Allowed After Appeal Filing
18
(16.2%)
Not Allowed After Appeal Filing
93
(83.8%)
Filing Benefit Percentile
18.9%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 16.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner MARTIN, PAUL C - Prosecution Strategy Guide

Executive Summary

Examiner MARTIN, PAUL C works in Art Unit 1653 and has examined 763 patent applications in our dataset. With an allowance rate of 41.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 35 months.

Allowance Patterns

Examiner MARTIN, PAUL C's allowance rate of 41.2% places them in the 8% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by MARTIN, PAUL C receive 2.77 office actions before reaching final disposition. This places the examiner in the 81% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by MARTIN, PAUL C is 35 months. This places the examiner in the 38% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +22.8% benefit to allowance rate for applications examined by MARTIN, PAUL C. This interview benefit is in the 68% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 12.6% of applications are subsequently allowed. This success rate is in the 8% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 19.1% of cases where such amendments are filed. This entry rate is in the 23% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 64.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 51% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 54.1% of appeals filed. This is in the 25% percentile among all examiners. Of these withdrawals, 55.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 84.2% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.5% of allowed cases (in the 61% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.